Curadev’s drug discovery slot machine

Most will call it madness: Selling your house to raise money and thinking Venture Capital firms will buy the dream of discovering new drugs from India. But Curadev lived that madness; hit a jackpot and is probably onto its next one. A rare success story, without investor money


A certain starkness marks the entrance to Curadev Pharma Private Limited. Freshly painted, the walls are bare; the reception desk is unmanned. The company does mostly science and doesn’t need a front desk; not yet. Ask them about the emptiness and co-founders Arjun Surya and Manish Tandon look at the ceiling and wistfully discuss how the AstraZeneca headquarters in Sweden had the hanging molecular structure of Omeprazole, the multi-billion-dollar anti-ulcer drug, greet visitors. “Maybe, one day, when one of our molecules becomes successful, we’ll have its molecular structure (mural) hanging here,” they say, almost in…

To access this content, you must purchase Quarterly, or log in if you are a member.

Read the full story now. Subscribe to The Ken

Stories on The Ken are available only for its subscribers. Join us now to get instant access.

Have an account?

Related stories

More stories in /Featured/Healthcare & /Reportage

See all in FeaturedHealthcare & Reportage

This story is exclusively for premium subscribers. Subscribe now to get access.

Read the full story now. Subscribe to The Ken

Why should I pay for reading your stories?

Lots of effort We go to lengths to put in time and resources required to get the most factual, honest stories out there.

Advertising independent Our primary allegiance will always be to our readers. We won't be swayed by our advertisers and investors.

We can't do all of this by giving away our journalism for free and selling our readers by the thousands to advertisers.

Get premium access